IMiDs mediate anti‐MM effects by binding to the E3 ubiquitin ligase cereblon (CRBN) [1, 2, 3], which subsequently increases degradation of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), culminating in downregulation of IRF4 and MYC expression leading to inhibition of MM cell growth [4, 5]. The gene discussed is CRBN; the disease is Miyoshi myopathy.